Rosetta Agrees to Buyout from Merck
Rosetta Inpharmatics (RSTA ) agreed to be acquired by Merck & Co. (MRK ) in a roughly $620 million stock deal. Terms: 0.2352 Merck share per Rosetta share.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.